These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 2469658)

  • 1. Alpha adrenergic antagonists for the treatment of symptomatic BPH.
    Lepor H
    Int J Clin Pharmacol Ther Toxicol; 1989 Apr; 27(4):151-5. PubMed ID: 2469658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The emerging role of alpha antagonists in the therapy of benign prostatic hyperplasia.
    Lepor H
    J Androl; 1991; 12(6):389-94. PubMed ID: 1722795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Embryologic development of the prostate. Insights into the etiology and treatment of benign prostatic hyperplasia.
    Shapiro E
    Urol Clin North Am; 1990 Aug; 17(3):487-93. PubMed ID: 1695777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of alpha blockers in the treatment of BPH: a critical review of clinical results.
    Von Heland M; Casale P
    Arch Esp Urol; 1994 Nov; 47(9):873-81; discussion 881-2. PubMed ID: 7530943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha-adrenergic mechanisms in dynamics of benign prostatic hypertrophy.
    Caine M
    Urology; 1988 Dec; 32(6 Suppl):16-20. PubMed ID: 2462300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of alfuzosin 10 mg once daily in the treatment of symptomatic benign prostatic hyperplasia.
    Kuritzky L; Rosenberg MT; Sadovsky R
    Int J Clin Pract; 2006 Mar; 60(3):351-8. PubMed ID: 16494652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Uroselectivity of alpha-1 antagonism in the treatment of benign prostatic hypertrophy: on the pharmacologic concept of the clinical approach].
    Jolliet P; Bourin M
    Therapie; 1998; 53(1):61-6. PubMed ID: 9773101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia.
    Shore N
    Expert Opin Investig Drugs; 2010 Feb; 19(2):305-10. PubMed ID: 20050813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk.
    Emberton M; Zinner N; Michel MC; Gittelman M; Chung MK; Madersbacher S
    BJU Int; 2007 Aug; 100(2):249-53. PubMed ID: 17617135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The natural history of benign prostatic hyperplasia.
    Fitzpatrick JM
    BJU Int; 2006 Apr; 97 Suppl 2():3-6; discussion 21-2. PubMed ID: 16507045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
    Roehrborn CG
    BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
    Tahmatzopoulos A; Kyprianou N
    Prostate; 2004 Apr; 59(1):91-100. PubMed ID: 14991869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical management of benign prostatic hyperplasia: a review.
    Magoha GA
    East Afr Med J; 1996 Jul; 73(7):453-6. PubMed ID: 8918007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doxazosin-alpha-1-adrenergic antagonists drug in the long-term (3 years). Management of benign prostatic hyperplasia.
    Dutkiewicz S
    Mater Med Pol; 1996; 28(3):93-102. PubMed ID: 9167419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of long-acting selective alpha-1 blockers in the treatment of benign prostatic hyperplasia.
    Lepor H
    Urol Clin North Am; 1990 Aug; 17(3):651-9. PubMed ID: 1695785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha blockade for the treatment of benign prostatic hyperplasia.
    Lepor H
    Urol Clin North Am; 1995 May; 22(2):375-86. PubMed ID: 7539182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Benign hypertrophy of the prostate: which treatment, for whom?].
    Schulman C
    Rev Med Brux; 1999 Sep; 20(4):A212-8. PubMed ID: 10523895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current treatment of BPH.
    Roylance P; Gibelin B; Espié J
    Biomed Pharmacother; 1995; 49(7-8):332-8. PubMed ID: 8562858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current drug therapy of benign prostatic hyperplasia].
    Schmidbauer CP; Madersbacher S
    Wien Med Wochenschr; 1996; 146(8):161-4. PubMed ID: 8767400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.